Study Finds Esketamine Nasal Spray More Likely to Induce Remission in Treatment-Resistant MDD Than Quetiapine Extended Release

“Over 32 weeks of follow-up, the percentage of patients with remission, the percentage of patients with a treatment response, and the change in the MADRS score from baseline favored esketamine nasal spray.”

Related Keywords

Johnson Spravato ,Reina Benabou ,Johnson ,Janssen Scientific Affairs ,Depression Rating Scale ,New England Journal ,